These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 28575321)

  • 21. Prognostic subgroups for remission, response, and treatment continuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial.
    Jakubovski E; Carlson JP; Bloch MH
    J Clin Psychiatry; 2015 Nov; 76(11):1535-45. PubMed ID: 26581028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transformed PANSS Factors Intended to Reduce Pseudospecificity Among Symptom Domains and Enhance Understanding of Symptom Change in Antipsychotic-Treated Patients With Schizophrenia.
    Hopkins SC; Ogirala A; Loebel A; Koblan KS
    Schizophr Bull; 2018 Apr; 44(3):593-602. PubMed ID: 28981857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recommendations to improve the positive and negative syndrome scale (PANSS) based on item response theory.
    Levine SZ; Rabinowitz J; Rizopoulos D
    Psychiatry Res; 2011 Aug; 188(3):446-52. PubMed ID: 21463902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score.
    Pilla Reddy V; Kozielska M; Suleiman AA; Johnson M; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
    Schizophr Res; 2013 May; 146(1-3):153-61. PubMed ID: 23473811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relationship between Positive and Negative Syndrome Scale (PANSS) schizophrenia severity scores and risk for hospitalization: an analysis of the CATIE Schizophrenia Trial.
    Glick HA; Li P; Harvey PD
    Schizophr Res; 2015 Aug; 166(1-3):110-4. PubMed ID: 26044113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impaired insight in schizophrenia: impact on patient-reported and physician-reported outcome measures in a randomized controlled trial.
    Lysaker PH; Weiden PJ; Sun X; O'Sullivan AK; McEvoy JP
    BMC Psychiatry; 2022 Aug; 22(1):574. PubMed ID: 36031632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: An analysis of clinical antipsychotic trials of intervention effectiveness (CATIE) data.
    Ozzoude M; Nakajima S; Plitman E; Chung JK; Kim J; Iwata Y; Caravaggio F; Takeuchi H; Uchida H; Graff-Guerrero A; Gerretsen P
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar; 89():207-213. PubMed ID: 30172739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia.
    Davidson M; Saoud J; Staner C; Noel N; Luthringer E; Werner S; Reilly J; Schaffhauser JY; Rabinowitz J; Weiser M; Luthringer R
    Am J Psychiatry; 2017 Dec; 174(12):1195-1202. PubMed ID: 28750582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Meta-analysis of the positive and Negative Syndrome Scale (PANSS) factor structure.
    Shafer A; Dazzi F
    J Psychiatr Res; 2019 Aug; 115():113-120. PubMed ID: 31128501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of antipsychotics on insight in schizophrenia: results from independent samples of first-episode and acutely relapsed patients.
    Misiak B; Frydecka D; Beszłej JA; Moustafa AA; Tybura P; Kucharska-Mazur J; Samochowiec A; Bieńkowski P; Samochowiec J
    Int Clin Psychopharmacol; 2016 Jul; 31(4):185-91. PubMed ID: 26836264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
    Lane HY; Chang YC; Liu YC; Chiu CC; Tsai GE
    Arch Gen Psychiatry; 2005 Nov; 62(11):1196-204. PubMed ID: 16275807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale. Reliability, comparability, and predictive validity.
    Bell M; Milstein R; Beam-Goulet J; Lysaker P; Cicchetti D
    J Nerv Ment Dis; 1992 Nov; 180(11):723-8. PubMed ID: 1431824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studies.
    O'Gorman C; Kapur S; Kolluri S; Kane J
    Hum Psychopharmacol; 2011; 26(4-5):282-90. PubMed ID: 21638329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
    Olié JP; Spina E; Murray S; Yang R
    Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute Antipsychotic Treatment of Children and Adolescents With Schizophrenia-Spectrum Disorders: A Systematic Review and Network Meta-Analysis.
    Pagsberg AK; Tarp S; Glintborg D; Stenstrøm AD; Fink-Jensen A; Correll CU; Christensen R
    J Am Acad Child Adolesc Psychiatry; 2017 Mar; 56(3):191-202. PubMed ID: 28219485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.
    Bobes J; Arango C; Garcia-Garcia M; Rejas J;
    J Clin Psychiatry; 2010 Mar; 71(3):280-6. PubMed ID: 19895779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol.
    Potkin SG; Weiden PJ; Loebel AD; Warrington LE; Watsky EJ; Siu CO
    Int J Neuropsychopharmacol; 2009 Oct; 12(9):1233-48. PubMed ID: 19419595
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE).
    Hermes ED; Sokoloff D; Stroup TS; Rosenheck RA
    J Clin Psychiatry; 2012 Apr; 73(4):526-32. PubMed ID: 22579152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of Antipsychotic Drugs for 24-Month Maintenance Treatment in First-Episode Schizophrenia: Evidence From a Community-Based "Real-World" Study.
    Zhang C; Chen MJ; Wu GJ; Wang ZW; Rao SZ; Zhang Y; Yi ZH; Yang WM; Gao KM; Song LS
    J Clin Psychiatry; 2016 Nov; 77(11):e1460-e1466. PubMed ID: 28076667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
    Tollefson GD; Andersen SW
    J Clin Psychiatry; 1999; 60 Suppl 5():23-9; discussion 30. PubMed ID: 10192404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.